Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 21 | 2026 | 241 | 5.980 |
Why?
|
| Chromatography, High Pressure Liquid | 18 | 2025 | 465 | 2.370 |
Why?
|
| Chromatography, Liquid | 14 | 2026 | 182 | 1.750 |
Why?
|
| Ovarian Neoplasms | 13 | 2015 | 415 | 1.430 |
Why?
|
| Rats | 29 | 2026 | 3735 | 1.320 |
Why?
|
| Rats, Sprague-Dawley | 19 | 2026 | 1766 | 1.180 |
Why?
|
| Reproducibility of Results | 16 | 2026 | 1081 | 1.150 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2021 | 863 | 1.040 |
Why?
|
| Microsomes, Liver | 3 | 2025 | 75 | 0.990 |
Why?
|
| Animals | 38 | 2026 | 16992 | 0.970 |
Why?
|
| Cytidine | 1 | 2026 | 5 | 0.960 |
Why?
|
| Deoxycytidine | 1 | 2026 | 38 | 0.930 |
Why?
|
| Glucuronides | 6 | 2025 | 25 | 0.930 |
Why?
|
| Nicotinic Acids | 3 | 2013 | 10 | 0.920 |
Why?
|
| Drug Monitoring | 2 | 2025 | 69 | 0.910 |
Why?
|
| Liver | 4 | 2026 | 511 | 0.900 |
Why?
|
| Solvents | 2 | 2015 | 113 | 0.840 |
Why?
|
| Anti-Retroviral Agents | 1 | 2025 | 160 | 0.830 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2015 | 734 | 0.810 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 231 | 0.770 |
Why?
|
| Biological Availability | 6 | 2021 | 116 | 0.750 |
Why?
|
| Health Personnel | 1 | 2025 | 277 | 0.730 |
Why?
|
| Pyridazines | 2 | 2013 | 16 | 0.730 |
Why?
|
| Flavonoids | 2 | 2025 | 100 | 0.720 |
Why?
|
| Propolis | 1 | 2021 | 7 | 0.710 |
Why?
|
| Weightlessness | 1 | 2021 | 27 | 0.670 |
Why?
|
| Neoplasms, Glandular and Epithelial | 6 | 2015 | 57 | 0.650 |
Why?
|
| Indoles | 2 | 2025 | 187 | 0.650 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 71 | 0.640 |
Why?
|
| Stilbenes | 2 | 2021 | 44 | 0.620 |
Why?
|
| Mycophenolic Acid | 3 | 2025 | 16 | 0.570 |
Why?
|
| Mannose | 3 | 2017 | 32 | 0.570 |
Why?
|
| Male | 27 | 2026 | 23409 | 0.540 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 432 | 0.510 |
Why?
|
| Serum | 1 | 2016 | 17 | 0.510 |
Why?
|
| Solubility | 5 | 2025 | 139 | 0.500 |
Why?
|
| Linear Models | 6 | 2026 | 317 | 0.500 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2013 | 57 | 0.470 |
Why?
|
| Drug Stability | 6 | 2026 | 129 | 0.460 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 1019 | 0.460 |
Why?
|
| Proline | 2 | 2015 | 40 | 0.460 |
Why?
|
| Sensitivity and Specificity | 3 | 2026 | 611 | 0.420 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 11 | 0.410 |
Why?
|
| Matrix Metalloproteinases | 1 | 2013 | 49 | 0.410 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 134 | 0.410 |
Why?
|
| Administration, Oral | 3 | 2021 | 260 | 0.400 |
Why?
|
| Blood Coagulation | 1 | 2013 | 29 | 0.390 |
Why?
|
| Ovary | 1 | 2013 | 113 | 0.390 |
Why?
|
| Limit of Detection | 4 | 2026 | 94 | 0.390 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 140 | 0.380 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2024 | 146 | 0.380 |
Why?
|
| Humans | 34 | 2025 | 43102 | 0.380 |
Why?
|
| Warfarin | 1 | 2013 | 67 | 0.370 |
Why?
|
| Antipyrine | 1 | 2012 | 4 | 0.370 |
Why?
|
| Curcumin | 1 | 2013 | 118 | 0.360 |
Why?
|
| Hindlimb Suspension | 1 | 2012 | 16 | 0.360 |
Why?
|
| Anticoagulants | 1 | 2013 | 122 | 0.360 |
Why?
|
| Menthol | 1 | 2012 | 23 | 0.360 |
Why?
|
| Female | 26 | 2026 | 24698 | 0.360 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 53 | 0.360 |
Why?
|
| Microsomes | 2 | 2022 | 55 | 0.350 |
Why?
|
| HIV Infections | 1 | 2025 | 2586 | 0.330 |
Why?
|
| Mice | 10 | 2026 | 6644 | 0.330 |
Why?
|
| Neoplasms | 2 | 2022 | 1377 | 0.320 |
Why?
|
| Species Specificity | 2 | 2024 | 286 | 0.320 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2015 | 97 | 0.320 |
Why?
|
| Methylcellulose | 1 | 2009 | 7 | 0.310 |
Why?
|
| Half-Life | 3 | 2015 | 63 | 0.300 |
Why?
|
| Isoxazoles | 1 | 2009 | 15 | 0.300 |
Why?
|
| Sucrose | 1 | 2009 | 33 | 0.300 |
Why?
|
| Anticonvulsants | 1 | 2009 | 40 | 0.300 |
Why?
|
| Nicotine | 1 | 2012 | 302 | 0.290 |
Why?
|
| Drug Compounding | 1 | 2009 | 93 | 0.290 |
Why?
|
| alpha-Tocopherol | 1 | 2008 | 27 | 0.280 |
Why?
|
| Nanoparticles | 3 | 2022 | 460 | 0.280 |
Why?
|
| Vitamin A | 1 | 2008 | 86 | 0.270 |
Why?
|
| Delayed-Action Preparations | 2 | 2013 | 74 | 0.270 |
Why?
|
| Piperidines | 2 | 2025 | 83 | 0.270 |
Why?
|
| Vitamins | 1 | 2008 | 81 | 0.260 |
Why?
|
| Tissue Distribution | 6 | 2025 | 240 | 0.260 |
Why?
|
| Genetic Variation | 3 | 2015 | 430 | 0.260 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 89 | 0.260 |
Why?
|
| Risk | 5 | 2015 | 287 | 0.260 |
Why?
|
| Nonprescription Drugs | 1 | 2006 | 3 | 0.260 |
Why?
|
| Niacin | 1 | 2006 | 23 | 0.250 |
Why?
|
| Middle Aged | 10 | 2025 | 12222 | 0.250 |
Why?
|
| Genome-Wide Association Study | 4 | 2015 | 423 | 0.240 |
Why?
|
| Diclofenac | 1 | 2024 | 5 | 0.220 |
Why?
|
| Plasma | 2 | 2022 | 38 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 3 | 2026 | 1869 | 0.220 |
Why?
|
| Texas | 2 | 2025 | 457 | 0.220 |
Why?
|
| MicroRNAs | 1 | 2010 | 518 | 0.220 |
Why?
|
| Glycosides | 1 | 2024 | 23 | 0.210 |
Why?
|
| Immunosuppressive Agents | 1 | 2025 | 94 | 0.210 |
Why?
|
| Nanospheres | 2 | 2014 | 7 | 0.210 |
Why?
|
| Alleles | 3 | 2021 | 352 | 0.210 |
Why?
|
| DNA Methylation | 2 | 2026 | 403 | 0.200 |
Why?
|
| Sulfites | 1 | 2023 | 13 | 0.200 |
Why?
|
| Phenols | 1 | 2024 | 107 | 0.200 |
Why?
|
| Biological Transport | 2 | 2021 | 204 | 0.190 |
Why?
|
| Hydrogen Sulfide | 1 | 2023 | 77 | 0.190 |
Why?
|
| Odds Ratio | 4 | 2015 | 587 | 0.190 |
Why?
|
| Glucuronidase | 1 | 2022 | 21 | 0.180 |
Why?
|
| Time Factors | 3 | 2012 | 1857 | 0.180 |
Why?
|
| Genotype | 6 | 2015 | 800 | 0.180 |
Why?
|
| Glucosides | 1 | 2021 | 21 | 0.180 |
Why?
|
| Fenoldopam | 1 | 2021 | 3 | 0.180 |
Why?
|
| Adult | 8 | 2025 | 13872 | 0.180 |
Why?
|
| Honey | 1 | 2021 | 15 | 0.180 |
Why?
|
| Nitriles | 2 | 2013 | 81 | 0.180 |
Why?
|
| Magnesium Hydroxide | 1 | 2021 | 2 | 0.170 |
Why?
|
| Antacids | 1 | 2021 | 3 | 0.170 |
Why?
|
| Antidiarrheals | 1 | 2021 | 4 | 0.170 |
Why?
|
| Aluminum Hydroxide | 1 | 2021 | 8 | 0.170 |
Why?
|
| Salicylates | 1 | 2021 | 9 | 0.170 |
Why?
|
| Bismuth | 1 | 2021 | 6 | 0.170 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 30 | 0.170 |
Why?
|
| Weightlessness Simulation | 1 | 2021 | 26 | 0.170 |
Why?
|
| Case-Control Studies | 6 | 2017 | 1285 | 0.170 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 118 | 0.170 |
Why?
|
| Polyethylene Glycols | 3 | 2022 | 108 | 0.170 |
Why?
|
| Pyrimidines | 2 | 2013 | 139 | 0.170 |
Why?
|
| Drug Combinations | 1 | 2021 | 104 | 0.170 |
Why?
|
| Organometallic Compounds | 1 | 2021 | 71 | 0.160 |
Why?
|
| Drug Interactions | 1 | 2021 | 150 | 0.160 |
Why?
|
| Gene Frequency | 1 | 2021 | 206 | 0.160 |
Why?
|
| Aminopyridines | 1 | 2020 | 26 | 0.160 |
Why?
|
| Risk Factors | 6 | 2015 | 3994 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2025 | 486 | 0.160 |
Why?
|
| Oxyquinoline | 1 | 2020 | 6 | 0.160 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2021 | 82 | 0.160 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2025 | 388 | 0.160 |
Why?
|
| Tongue | 1 | 2019 | 16 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2020 | 47 | 0.150 |
Why?
|
| Aged | 7 | 2017 | 8214 | 0.150 |
Why?
|
| Pharmaceutical Solutions | 2 | 2015 | 5 | 0.150 |
Why?
|
| Chloroquinolinols | 1 | 2018 | 4 | 0.150 |
Why?
|
| Quantitative Trait Loci | 2 | 2015 | 88 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 458 | 0.140 |
Why?
|
| Kinetics | 2 | 2024 | 695 | 0.140 |
Why?
|
| Protein Binding | 3 | 2015 | 1082 | 0.130 |
Why?
|
| Temperature | 2 | 2009 | 313 | 0.130 |
Why?
|
| Rats, Inbred F344 | 3 | 2021 | 258 | 0.120 |
Why?
|
| Colonic Polyps | 1 | 2017 | 71 | 0.120 |
Why?
|
| Adenoma | 1 | 2017 | 96 | 0.120 |
Why?
|
| Molecular Structure | 3 | 2024 | 570 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2014 | 95 | 0.120 |
Why?
|
| Copper Radioisotopes | 1 | 2015 | 9 | 0.120 |
Why?
|
| Phototherapy | 1 | 2015 | 25 | 0.110 |
Why?
|
| Veratrum Alkaloids | 1 | 2015 | 2 | 0.110 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2015 | 44 | 0.110 |
Why?
|
| Lutetium | 1 | 2015 | 3 | 0.110 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 92 | 0.110 |
Why?
|
| Radioisotopes | 1 | 2015 | 17 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 62 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2015 | 77 | 0.110 |
Why?
|
| Gonadotropins | 1 | 2014 | 27 | 0.110 |
Why?
|
| Anilides | 1 | 2014 | 28 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 56 | 0.110 |
Why?
|
| Cyclohexanes | 1 | 2014 | 30 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 93 | 0.110 |
Why?
|
| Bilirubin | 1 | 2014 | 18 | 0.110 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 50 | 0.110 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 58 | 0.110 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 69 | 0.110 |
Why?
|
| Itraconazole | 1 | 2013 | 13 | 0.100 |
Why?
|
| Endometriosis | 1 | 2015 | 83 | 0.100 |
Why?
|
| Injections, Intramuscular | 1 | 2013 | 21 | 0.100 |
Why?
|
| Polysorbates | 1 | 2013 | 11 | 0.100 |
Why?
|
| Antibodies | 1 | 2014 | 144 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 36 | 0.100 |
Why?
|
| Polyglycolic Acid | 1 | 2013 | 48 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 228 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 2676 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 81 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2014 | 1604 | 0.100 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2013 | 2 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2015 | 321 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2013 | 11 | 0.100 |
Why?
|
| Acetaminophen | 1 | 2013 | 30 | 0.100 |
Why?
|
| Biotransformation | 1 | 2013 | 69 | 0.100 |
Why?
|
| Lactic Acid | 1 | 2013 | 112 | 0.100 |
Why?
|
| Hydrolysis | 1 | 2013 | 97 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 368 | 0.100 |
Why?
|
| Reference Standards | 2 | 2013 | 55 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 968 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 291 | 0.090 |
Why?
|
| Drug Synergism | 1 | 2013 | 195 | 0.090 |
Why?
|
| Gold | 1 | 2014 | 156 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2013 | 174 | 0.090 |
Why?
|
| Radioimmunoassay | 1 | 2012 | 70 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2013 | 169 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 218 | 0.090 |
Why?
|
| Cotinine | 1 | 2012 | 44 | 0.090 |
Why?
|
| Administration, Inhalation | 1 | 2012 | 92 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2015 | 863 | 0.090 |
Why?
|
| Models, Animal | 1 | 2012 | 151 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 512 | 0.090 |
Why?
|
| Ethanol | 1 | 2013 | 224 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 10 | 0.080 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2010 | 14 | 0.080 |
Why?
|
| Metabolomics | 3 | 2017 | 95 | 0.080 |
Why?
|
| Lymphokines | 1 | 2010 | 18 | 0.080 |
Why?
|
| Biosynthetic Pathways | 1 | 2010 | 14 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 28 | 0.080 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 230 | 0.080 |
Why?
|
| Haplotypes | 1 | 2010 | 197 | 0.080 |
Why?
|
| Kidney | 2 | 2024 | 372 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 291 | 0.080 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2010 | 140 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 449 | 0.080 |
Why?
|
| Refrigeration | 1 | 2009 | 4 | 0.080 |
Why?
|
| Transfection | 1 | 2010 | 532 | 0.080 |
Why?
|
| Drug Storage | 1 | 2009 | 28 | 0.080 |
Why?
|
| Suspensions | 1 | 2009 | 48 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 495 | 0.070 |
Why?
|
| Binding Sites | 1 | 2010 | 671 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1596 | 0.070 |
Why?
|
| gamma-Tocopherol | 1 | 2008 | 19 | 0.070 |
Why?
|
| Sex Factors | 1 | 2012 | 1028 | 0.070 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 104 | 0.070 |
Why?
|
| Smoking | 1 | 2014 | 1024 | 0.070 |
Why?
|
| Caco-2 Cells | 1 | 2025 | 64 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2025 | 127 | 0.060 |
Why?
|
| Monosaccharides | 1 | 2024 | 13 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2008 | 469 | 0.050 |
Why?
|
| Dogs | 1 | 2024 | 204 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2853 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 1723 | 0.050 |
Why?
|
| Methanol | 1 | 2023 | 22 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 694 | 0.050 |
Why?
|
| Sulfides | 1 | 2023 | 78 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2015 | 408 | 0.050 |
Why?
|
| Swine | 1 | 2023 | 212 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1009 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2022 | 97 | 0.040 |
Why?
|
| Glucuronates | 1 | 2021 | 8 | 0.040 |
Why?
|
| Liposomes | 1 | 2022 | 132 | 0.040 |
Why?
|
| Sulfates | 1 | 2021 | 26 | 0.040 |
Why?
|
| Glucuronosyltransferase | 1 | 2021 | 29 | 0.040 |
Why?
|
| Intestines | 1 | 2021 | 71 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 132 | 0.040 |
Why?
|
| Hydrazones | 1 | 2020 | 11 | 0.040 |
Why?
|
| Chemistry, Physical | 1 | 2020 | 50 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 65 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 277 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 280 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2020 | 229 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 184 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 1154 | 0.030 |
Why?
|
| Hypoxanthine | 1 | 2017 | 2 | 0.030 |
Why?
|
| Intestinal Polyps | 1 | 2017 | 4 | 0.030 |
Why?
|
| Xanthine | 1 | 2017 | 4 | 0.030 |
Why?
|
| Caffeine | 1 | 2017 | 28 | 0.030 |
Why?
|
| Urea | 1 | 2017 | 46 | 0.030 |
Why?
|
| Nuchal Cord | 1 | 2015 | 2 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 638 | 0.030 |
Why?
|
| United States | 1 | 2006 | 5205 | 0.030 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 63 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 97 | 0.030 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 11 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2014 | 2157 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 84 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 110 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 148 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 667 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 173 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 158 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 150 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 16 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 310 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 150 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 129 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2014 | 40 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 67 | 0.030 |
Why?
|
| Freeze Drying | 1 | 2013 | 29 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2013 | 52 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 347 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 333 | 0.020 |
Why?
|
| Ligands | 1 | 2014 | 388 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 245 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 186 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 861 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2014 | 176 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 735 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 526 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 1759 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 1177 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 704 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2015 | 2544 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 5080 | 0.010 |
Why?
|
| Adolescent | 1 | 2015 | 6081 | 0.010 |
Why?
|